Contacts
Theme Leader
Adrian L Harris, Professor of Medical Oncology. Internationally renowned as a translational researcher in the fields of angiogenesis and hypoxia as applied to cancer. Theme leadership, breast cancer.
Theme Liaison Contact:
Sandie Wellman sandie.wellman@medonc.ox.ac.uk Tel: 01865 235294
Co-theme Leader
Prof. Mark Middleton, NHS Consultant Oncologist, Director of the Early Phase Cancer Trials Unit, Clinical Director of Oncology at Oxford University Hospitals NHS Trust. Recruited >400 patients to over 30 early phase cancer studies in the last 5 years. Established translational researcher in melanoma, leading national and international trials involving biomarker-driven patient selection. Taxane studies, phase I trials, melanoma, link to Genomic Medicine.
Key researchers
Prof. Gillies McKenna, Heads the University Department of Oncology and is director of the Gray Institute. Has shown that the PI3K-PTEN-Akt pathway presents targets that can be manipulated in the clinic to enhance the effects of radiotherapy. Scientific collaborator.
Prof. Thomas Helleday, Group leader at the Gray Institute, pioneered the concept of synthetic lethality. Scientific work has translated into the use of PARP inhibitors in the treatment of patients with BRCA deficient tumours, and to the BRC’s 6-MP trial.
Prof. Freddie Hamdy, NIHR Senior Investigator, Professor of Surgery and Director of Surgery and Oncology at Oxford University Hospitals NHS Trust. He leads the Surgical Innovation & Evaluation Theme, and has pioneered novel surgical techniques in urological cancer. Leading translational researcher, Chief Investigator of ProtecT, the largest trial of treatment for prostate cancer in the world. Surgical trials, biobanking.
Dr Ricky Sharma, Director of the Thames Valley Cancer Research Network & clinician scientist at the Gray Institute. Chief Investigator in national trials of radiotherapy for GI cancer. Synthetic lethality as applied to radiotherapy & platinum chemotherapy.
Prof. Tim Maughan, Clinical Director of the Gray Institute and Director of R&D in the Division of Surgery and Oncology in ORHT. Chief investigator of national colorectal trials using molecular selection of therapy. Colorectal cancer.
Prof. Bass Hassan, Clinician scientist at the Dunn School of Pathology, is principal investigator for Eurosarc and EuroBoNet consortium. Bone sarcoma trials, link to Musculoskeletal Biomedical Research Unit.
Prof. Runjan Chetty, BRC Director of Translational Pathology, leads the pathology and biobanking within the Oxford BioRepository, and links to the NIHR Bioresource.
Prof. Ian Tomlinson provides expertise in pathology and Genomic Medicine.
